






























The major environmental risk factors for type II 
diabetes  are obesity and a sedentary lifestyle [1], and 
the dramatic increase in the rates of type II diabetes in 
recent years has been attributed, primarily, to the 
striking rise in obesity worldwide [2]. Adipose tissue is 
absolutely required for glucose homeostasis. Indeed, 
subjects with lipoatrophy and transgenic animals that 
are engineered to lack adipose tissue are extremely 
insulin resistant [3]. This seems therefore to indicate 
that storage of energy in adipocytes favors insulin 
sensitivity. Adipose tissue dysfunction, which is 
associated with obesity is the key factor of obesity-
related insulin resistance and type II diabetes. Since 
adipose tissue only contributes minimally to glucose 
disposal, signaling pathways might exist from adipose 
tissue to muscle and other insulin sensitive tissues. Both 
proteins and lipids have been proposed as non-mutually 
exclusive signaling molecules, which can affect the 
muscle. A first group of important mediators consists of 
fatty acids. Since the original observation by Randle, it 
has been established that increased fatty acid 
concentrations in the muscle decrease glucose me-

























































that affect insulin sensitivity in both muscle and liver 
and which are derived from adipose tissue are 
adipokines. Adipokines are factors secreted by the 
different cell compartments of white adipose tissue 
(WAT), such as adipocytes or macrophages, and were 
initially characterized as regulators of metabolic 
processes, such as regulation of food intake, energy 
homeostasis, adipocyte differentiation, or insulin 
sensitivity.  Subsequently, it was found that adipokines 
could modulate inflammatory processes. These 
adipokines include WAT-specific factors, such as 
leptin, adiponectin, and well-known cytokines secreted 
by several cell types, such as TNF-alpha, IL-6, IL-8, IL-
1, or monocyte chemoattractant protein-1 [5]. In our 
recent publication we identify the CXCL5 chemokine as 
one of these signaling molecules secreted in adipose 
tissue that have major implications in insulin sensitivity 
in muscle cells [6]. 
 
CXCL5 or epithelial neutrophil activating peptide 
(ENA-78) is a cytokine belonging to the family of 
chemokines that is mainly implicated in the chemotaxis 
of inflammatory cells through the generation of local 
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recruiter of neutrophils and involved in their activation. 
This C–X–C chemokine has been implicated in 
pulmonary disease, lung cancer, arthritis, and other 
pathological states [7, 9, 10]. In our paper we show that 
CXCL5 is a new chemokine secreted by adipose tissue 
resident macrophages and that circulating CXCL5 is 
highly increased during obesity in both mice and 
humans. CXCL5 is able to inhibit insulin action in 
muscle by activating the Jak/STAT/SOC signaling 
pathway showing that CXCL5 can induce insulin 












































sulin-resistant patients compared to non-insulin-
resistant obese patients. Moreover, CXCL5 is directly 
regulated by TNFα in both adipose tissue and 
macrophages by NFκB activation, suggesting that 
CXCL5 mediates the effects of TNFα in insulin 
resistance. Most importantly, inhibition of signaling 
from CXCR2, which is the CXCL5 receptor, by 
injection of neutralizing anti-CXCL5 antibody or 
selective antagonist to CXCR2 in insulin-resistant-
obese mice improves both insulin sensitivity and 
glucose clearance. In summary our data show that 
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conditions associated to obesity-induced diabetes 
 
In addition to insulin resistance, obese diabetic patients 
are at high risk to develop associated pathologies, 
including, but not limited to atherosclerosis, 
retinopathies, or other inflammatory diseases. This is 
represented in figure 1. Interestingly, a major common 
feature of these pathologies is inflammation. Since 
CXCL5 is an inflammatory factor, and since its levels 
are increased in obese patients, we could speculate that 
CXCL5 is at the origin of obesity- associated co-
morbidities. Furthermore, the CXCL5 receptor CXCR2 
is expressed in cells other than muscle cells, such as 
endothelial, pulmonary, or intestinal epithelial cells. In 
this context, it is interesting the recently suggested 
correlation between obesity and asthma [11]. Strikingly, 
exacerbation of asthma has been also correlated with 
increased expression of both CXCL5 and its receptor 
CXCR2 [12]. Atherosclerosis is another obesity-related 
risk factor in which CXCR2 could play an important 
role. This receptor is found in macrophage-rich intimae 
in human atherosclerotic lesions, and it has been shown 
to have a major impact on macrophage accumulation in 
advanced lesions [13]. CXCR2 ligands, such as GRO-α 
participate in this macrophage accumulation and lesion 
progression, although they might not have a causative 
role [14], but rather contribute to disease progression. 
CXCL5 could also participate in this process. 
 
Secondary to obesity-induced diabetes is the 
development of retinopathy. Development of diabetic 
retinopathy is a multifactorial process, and affects as 
much as 30% of type II diabetic patients. Much of the 
damage of retinopathy results from leakage of retinal 
blood vessels and inadequate retinal perfusion. [15] 
Sustained hyperglycemia in diabetes affects various 
vasoactive factors, such as vascular endothelial growth 
factor [16]. These factors, which are all interrelated, 
contribute to development of structural and functional 
changes in diabetic retinopathy, such as breakdown of 
the blood–retina barrier. Participation of CXCL5 in the 
development of retinopathy was suggested by the 
increased levels of this chemokine found in retinopathy 
diabetic patients [17]. 
 
Finally, but not limited to, CXCL5 could be also 
involved in the development of obesity-related 
inflammatory bowel disease. Although obesity has not 
been directly linked to the pathophysiology of 
inflammatory bowel disease (IBD), increased 
macrophage numbers as well as enhanced production of 
proinflammatory adipokines in obese patients may 
create a favorable environment for disease progression 
in intestinal inflammation and IBD [18]. Increased basal 
cytokine levels associated with obesity, both due to 
increased adipocytes numbers and size may predispose 
to more severe outcomes in IBD patients. Recent 
observations indicating that fat tissue is also associated 
with immune responses also suggest a link between 
obesity and gut inflammation [19].  The pro-
inflammatory effects of CXCL5 are widely accepted. 
Furthermore, it was shown that CXCR2 plays a crucial 
pathophysiological role in experimental ulcerative 
colitis in mice [20]. In humans, a marked increase in 
ENA-78 has been reported in ulcerative colitis patients 
[21], and has been shown to be localized to colonic 
epithelial cells in IBD tissues [21, 22]. Taken together, 
these observations suggest that the increased CXCL5 
circulating levels observed during obesity could 
contribute to the development or progression of IBD.  
 
Studies aiming to elucidate the role of WAT-secreted 
CXCL5 in all these obesity-related pathologies are 
likely to be forthcoming in the near future. Inhibiting 
CXCL5 secretion or function in obese individuals not 
only ameliorate their insulin sensitivity, but could also 
decrease the risk of developing other major obesity-
related pathologies. 
 
CXCL5 gene polymorphisms 
 
It is now accepted that type II diabetes is, in part, 
inherited.  Family studies have revealed that first degree 
relatives of individuals with type II diabetes are about 3 
times more likely to develop the disease than 
individuals without a positive family history of the 
disease [23].  It has also been shown that concordance 
rates for monozygotic twins, which have ranged from 
60-90%, are significantly higher than those for 
dizygotic twins.  It is therefore clear that type II 
diabetes has a strong genetic component. Candidate 
genes identified sofar include the nuclear receptor 
PPARγ, the sulfonylurea receptor ABCC8, the 
potassium channel Kir6.2, or the intracellular calcium-
dependent cystein protease calpain 10. Taking into 
account the relative importance of CXCL5 in the 
development of insulin resistance we can hypothesize 
that this chemokine could also be a type II diabetes 
susceptibility gene. Indeed several polymorphisms in 
the CXCL5 gene have been described. Interestingly, a -
156G to C polymorphism in the promoter of the gene 
has been associated to increased expression and plasma 
concentration of CXCL5. It cannot be excluded that this 
or other activating polymorphisms are overrepresented 
in type II diabetes and obese subjects. 
 
Anti CXCL5-CXCR2 based therapies 
 
Despite the list of new and classical agents designed for  
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thiazolidinediones, biguanides, meglitinides, or 
sulphonylureas is increasingly long, a major challenge 
remains because even using the more aggressive 
therapy, glycemic control in type II diabetic patients 
may still deteriorate. Our study may provide a new 
therapeutic target. We show that inhibition of the 
CXCL5-CXCR2 axis, both by CXCR2 antagonists or 
CXCL5 blocking antibodies decreases glycemia in mice 
models of diabetes. Long term treatments are currently 
being evaluated in our laboratory. The most interesting 
feature of this newly identified target is that is directed 
not only for insulin resistance treatment, but could also 
target diabetes-associated co-morbidities. It is 
interesting to notice, at some extent, similarities 
between other insulin-sensitizing drugs, such as 
metformin and anti-CXCL5 therapy. Similar to 
metformin, CXCL5 antagonism restores insulin 
sensitivity, has anti-atherosclerosis effects, and could be 
even beneficial as anti-cancer agent.  From this 
perspective, anti-CXCL5 therapy could be also 
considered as anti-aging therapy (reviewed in [24]). 
Safety studies of the tested molecules, as well as 
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